News Related to SERPINA1

Related coverage linked through entity extraction aliases.

Krystal Biotech reports Q1 2026 progress on KB803, KB801 and VYJUVEK expansion

May 04, 2026

Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.

YolTech Therapeutics Receives FDA Clearance for Phase 2/3 Study of YOLT-202 in AATD

Mar 14, 2026

YolTech Therapeutics received FDA approval for its IND application for YOLT-202, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Interim data from an ongoing trial showed rapid increases in AAT levels to normal range with favorable safety.